EurekAlert!

A study led by CIC bioGUNE delves into the complexity of the most aggressive form of prostate cancer

Cancer cannot be understood as a single, uniform disease. The more we delve into studying each type of tumor, the more we recognize the need to subclassify the disease. This concept has led to what we ...
Yahoo Finance

VectivBio Announces Completion of Enrollment for Colon-In-Continuity (CIC) Cohort of STARS Pivotal Phase 3 Study Investigating Apraglutide in Short Bowel Syndrome with ...

BASEL, Switzerland, Nov. 03, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for ...
Pharmabiz

VectivBio completes enrollment of CIC cohort of STARS pivotal phase 3 study of apraglutide in short bowel syndrome with intestinal failure

VectivBio Holding AG (VectivBio), a clinical-stage biopharmaceutical company, announced the completion of enrollment of the Colon-in-Continuity (CIC) cohort for the company’s phase 3 STARS (STudy of ...
EurekAlert!

CIC bioGUNE leads a study showing that multi-omic data can identify silent and stable risk profiles in healthy individuals

CIC bioGUNE leads a study showing that multi-omic data can identify silent and stable risk profiles in healthy individuals The study, conducted using local cohorts from the Basque Country, ...
Business Wire

Ironwood Pharmaceuticals Presents Positive Final Data from STARS Nutrition, a Phase II Study of Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) and Colon ...

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a global GI-focused healthcare company, presented positive final data from the company’s Phase II STARS Nutrition program during ...
Yahoo Finance

VectivBio Reports Positive Interim Clinical Data from STARS Nutrition, a Phase 2 Study Investigating Apraglutide in Short Bowel Syndrome with Intestinal Failure Patients (SBS ...

BASEL, Switzerland, Oct. 13, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for ...
Business Wire

Synergy Presents New Insights at Digestive Disease Week (DDW) Examining Patient and Physician Perceptions and Experiences with Chronic Idiopathic Constipation (CIC)

NEW YORK--(BUSINESS WIRE)--Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced new insights that highlighted the frustrations many patients with chronic idiopathic constipation (CIC) feel with ...
Monthly Prescribing Reference

Positive Phase 3 Results for Chronic Idiopathic Constipation Drug

Synergy announced additional clinical data from two Phase 3 trials, Study-00 and Study-03, evaluating the efficacy and safety of plecanatide for the treatment of chronic idiopathic constipation (CIC).